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Theobjective of this studywas to determine the point after sugammadex administration atwhich sufficient or insufficient dose could
be determined, using first twitch height of train-of-four (T1 height) or train-of-four ratio (TOFR) as indicators. Groups A and B
received 1mg/kg and 0.5mg/kg of sugammadex, respectively, as a first dose when the second twitch reappeared in train-of-four
stimulation, andGroups C andD received 1mg/kg and 0.5mg/kg of sugammadex, respectively, as the first dose at posttetanic counts
1–3. Five minutes after the first dose, an additional 1mg/kg of sugammadex was administered and changes in T1 height and TOFR
were observed. Patients were divided into a recovered group and a partly recovered group, based on percentage changes in T1 height
after additional dosing. T1 height and TOFR during the 5min after first dose were then compared. In the recovered group, TOFR
exceeded 90% in all patients at 3min after sugammadex administration. In the partly recovered group, none of the patients had a
TOFR above 90% at 3min after sugammadex administration. An additional dose of sugammadex can be considered unnecessary
if the train-of-four ratio is ≥90% at 3min after sugammadex administration. This trial is registered with UMIN000007245.
1. Introduction
The recommended dose of sugammadex is determined based
on the body weight of the patient and is set at 2mg/kg of
patient body weight for reversal of moderate neuromuscular
block (NMB), that is, upon reappearance of the second twitch
(T2) in train-of-four (TOF) stimulation, and at 4mg/kg
of patient body weight for reversal of deep NMB, that is,
posttetanic count (PTC) 1-2. These recommendations have
been defined by clinical consensus as the dose capable of
exerting a reversal effect on NMB based on patient body
weight, irrespective of individual differences. As a result,
some patients administered the recommended dose receive
more sugammadex than necessary. For example, moderate
NMB is sufficiently reversed by 1mg/kg sugammadex in
some patients [1], and the recommended dose of 2mg/kg
sugammadex would constitute an overdose in such patients.
An insufficient dose can lead to a return to NMB after
temporary block reversal [2, 3], and avoiding underdosing is
therefore essential. However, if it were possible to ascertain
shortly after sugammadex administration that a patient
required less than the recommended dose, adjustments
could be made. Safe reduction of the sugammadex dose in
individual patients would also contribute to reducing drug
costs. In addition, if NMB is required again for reoperation
after sugammadex administration, a dose of the blocking
agent rocuronium or vecuronium sufficient to overcome the
reversal effect of sugammadex must be administered to rein-
stigate blocking. In such situations, the amount of blocking
agent required to reinstigate blocking could potentially be
minimized if the appropriate sugammadex dose has been
used. Recent research suggests that sugammadex, 1.0mg/kg,
rapidly and effectively reverses rocuronium-induced neuro-
muscular block which has recovered spontaneously to four
twitches of TOF stimulation [4]. However, there is little
research that considers the possibilities of safe reduction of
the sugammadex dose for reversal of moderate or deepNMB.
Against this background, we investigated the possibility of
predicting whether the administered dose of sugammadex
would be sufficient or insufficient by monitoring first twitch
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height of TOF (T1 height) and TOF ratio (TOFR) during
recovery in adult patients receiving sugammadex. The pri-
mary objective of this study was thus to determine the point
shortly after sugammadex administration at which sufficient
or insufficient dose could be determined, using T1 height or
TOFR as indicators.
2. Materials and Methods
The study was conducted at Asahikawa Medical University
Hospital, Japan. The study protocol was approved by the
ethics committee at the university and informed consent was
obtained from all patients prior to enrolment. The protocol
was reported to the UMIN clinical trials registry and given
the code number UMIN000007245.
Subjects comprised 32 patients (18male, 14 female) sched-
uled to undergo general anesthesia with tracheal intubation.
ASA physical status was I-II, and patients with diabetes and
neuromuscular disorders were excluded. Patients ranged in
age from 20 to 82 years. Anesthesia was induced without
premedication, using 1.5–2mg/kg propofol, 0.3𝜇g/kg/min
remifentanil, and oxygen, and was maintained with 1.5–2%
sevoflurane, 0.1–0.25 𝜇g/kg/min remifentanil, oxygen, and
air. Rocuronium was administered at 0.6mg/kg before tra-
cheal intubation, then subsequently at 0.2-0.3mg/kgwhenT2
reappeared inTOF stimulation. Routinemonitoring included
electrocardiography, pulse oximetry, and noninvasive blood
pressure monitoring. Skin temperature of the hand was
measured and kept above 33∘C. Central temperature was
monitored at the esophagus and kept above 35∘C. During
maintenance of anesthesia, end-tidal Pco2 was kept between
33 and 42mmHg. NMB was monitored using a TOF-Watch
SX (Organon Ireland, Dublin, Ireland) and the accelography
of the adductor pollicis muscle response to ulnar nerve
stimulation was recorded. The TOF mode of stimulation
(2Hz; 0.2ms) was applied at 15 s intervals throughout the
procedure. Stabilizationwas achieved with a 5 s, 50Hz tetanic
stimulation. One minute after this tetanic stimulation, the
fingers were fixated and completely immobilized, except
for the thumb by using hand adapter (TOF-Watch Hand
Adapter, Organon). After repetitive TOF stimulation for
at least 3min, calibration occurred by pressing the CAL
button. Supramaximal stimuli were applied after automatic
calibration of the device after an initial tetanic stimulus (CAL
2 mode). After calibration, the TOF-Watch SX was switched
to the repetitive TOF stimulation again, which lasted until
the end of anesthesia. NMB agent was not to be administered
until at least 3min after calibration, to check for correct setup.
No preload was used, but we fixed the patient’s arm and other
4 fingers throughout the entire duration of the procedure
to avoid artifacts caused by movement. All neuromuscular
monitoring data were transferred to a personal computer
using a fiber-optic cable (TOF-Link), and saved using TOF-
Watch SX Monitor software.
In the present study, a lower dose of sugammadex than
what is recommended was administered as the first dose.
Eight patients each were assigned randomly to 4 groups
differentiated by extent of NMB remaining before first dose
of sugammadex and size of first sugammadex dose. Groups
A and B received 1mg/kg and 0.5mg/kg of sugammadex,
respectively, as the first dose when T2 reappeared in TOF
stimulation, while Groups C and D received 1mg/kg and
0.5mg/kg of sugammadex, respectively, as the first dose at
PTC 1–3 in posttetanic stimulation. In each patient, T1 height
and TOFR values were recorded every 15 s for 5min after
first dose of sugammadex. Five minutes after first dose, an
additional 1mg/kg of sugammadex was administered and
changes in T1 height and TOFR were observed. Patients were
divided into a recovered group and a partly recovered group
based on percentage change in T1 height after the additional
dose. T1 height and TOFR values every minute for 5min
after the first dose of sugammadex were then compared. The
recovered group was defined as having <10% increase in T1
height after 3min of the additional dose of sugammadex.The
partly recovered group was defined as having ≥10% increase
in T1 height after 3min of the additional dose of sugammadex
(Figure 1). After observations, all patients received a last addi-
tional dose of sugammadex so that the total dose matched
the recommended dose stated in the product documentation,
and recovery from NMB was confirmed in all patients after
30min of the last additional dose. After recording all data,
administration of sevoflurane and remifentanil was stopped
and sufficient spontaneous breathing and patient response to
verbal commands was confirmed. The airway tube was then
removed.
The sample size was determined based on data for eight
patients (two patients each for Groups A, B, C, and D)
obtained from a preliminary study. There were 2 patients in
the recovered group and 6 patients in the partly recovered
group. T1 height at 3min after first dose of sugammadex
was 69.5 ± 10.6 in the recovered group and 40.0 ± 30.7 in
the partly recovered group. Obtaining statistically significant
results with 𝛼 = 0.05 and a power of 0.8 required 28 patients
in total. Considering dropouts, we enrolled 32 patients in
total.
T1 height and TOFR were each compared between the
recovered and partly recovered groups using an unpaired 𝑡-
test. Characteristics of patients in Groups A to D were tested
using a Kruskal-Wallis test formale-female ratio and one-way
analysis of variance for age, height, weight, and body mass
index. A significance level of 𝑃 < 0.05 was set for each test.
3. Results
All enrolled patients completed the study. The breakdown of
Groups A to D is shown in Table 1. No significant differences
were seen between the characteristics of patients in Groups A
to D (Table 1).
The recovered group included 6 of the 8 patients in
Group A. The remaining 2 patients in Group A and all
patients of Groups B–D were classed as partly recovered
group (Table 2). T1 height and TOFR values from 1 to 5min
after the first dose and from 1 to 3min after the additional
dose of sugammadex in the recovered and partly recovered
groups are shown in Tables 3 and 4. T1 height and TOFR
values differed significantly between the recovered and partly
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after 3min of the additional dose of Sug after 3min of the additional dose of Sug
First dose of Sug: 1mg/kg First dose of Sug: 0.5mg/kg First dose of Sug: 1mg/kg First dose of Sug: 0.5mg/kg
1–3 When: PTC 1–3
Figure 1: Patient flow through the study. Groups A and B received 1mg/kg and 0.5mg/kg of sugammadex (Sug), respectively, as a first
dose when the second twitch (T2) reappeared in train-of-four stimulation (TOF), and Groups C and D received 1mg/kg and 0.5mg/kg of
Sug, respectively, as the first dose at posttetanic counts 1–3 (PTC 1–3). Five minutes after the first dose, an additional 1mg/kg of Sug was
administered and changes in first twitch height of TOF (T1 height) and train-of-four ratio (TOFR) were observed. Patients were divided into
a recovered group and a partly recovered group, based on percentage changes in T1 height after additional dosing. T1 height and TOFR during
the 5min after first dose were then compared.
Table 1: Patient characteristics.
Sex (M/F) Age (years) Height (cm) Weight (kg) BMI (kg/cm2)
Group A (𝑛 = 8) 5/3 49.5 ± 18.9 167.0 ± 10.9 62.5 ± 8.6 22.4 ± 1.3
Group B (𝑛 = 8) 5/3 66.1 ± 9.4 160.4 ± 10.2 58.9 ± 9.6 23.1 ± 4.2
Group C (𝑛 = 8) 3/5 60.2 ± 19.7 158.3 ± 8.7 60.1 ± 13.3 24.0 ± 5.0
Group D (𝑛 = 8) 5/3 52.5 ± 23.0 163.0 ± 12.2 66.4 ± 12.5 25.0 ± 4.0
Values are given as mean ± SD or number. No significant differences are seen between groups.
Sug: sugammadex; BMI: body mass index.
recovered groups at all time points from 1 to 5min after the
first dose and from 1 to 3min after the additional dose of
sugammadex. In the recovered group, TOFR exceeded 90%
in all patients at 3min after the first dose of sugammadex
administration. In the partly recovered group, none of the
patients had a TOFR above 90% at 3min after the first dose
of sugammadex administration.
4. Discussion
Recovered group patients only came from Group A, and all
patients of Groups B–D were in the partly recovered group.
Six of the 8 patients in Group A were in the recovered group
and 2 were in the partly recovered group, a finding in line
with other studies on the optimum dose of sugammadex
[2, 5]. Although some patients given 1mg/kg sugammadex
while in moderate NMB (when T2 reappeared in TOF)
recovered to the same extent as those given 2mg/kg, a large
variation existed between patients and some only showed
partial recovery.
Also this result was consistent with the findings of Duva-
ldestin et al. that sugammadex, 0.5mg/kg and 1.0mg/kg,
could not provide rapid reversal of deep rocuronium-induced
NMB under sevoflurane maintenance anesthesia [6]. T1
height and TOFR both differed significantly between the
recovered and partly recovered groups at all time points from
1 to 5min after the first dose of sugammadex administration.
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Table 2: Breakdown of recovered group and partly recovered group.
Sug dose timing Sug first dose (mg/kg) Recovered group/partly recovered group
Group A (𝑛 = 8) T2 1 6/2
Group B (𝑛 = 8) T2 0.5 0/8
Group C (𝑛 = 8) PTC1-3 1 0/8
Group D (𝑛 = 8) PTC1-3 0.5 0/8
Sug: sugammadex.
















































































𝑃 values <0.0001 <0.0001 0.0001 0.0008 0.0018 0.0085 0.0272 0.0438
Values are given as mean (min–max). T1 height values differed significantly between the recovered and partly recovered groups at all time points (𝑃 < 0.05).
T1: height first twitch height of TOF.
















































































𝑃 values <0.0001 <0.0001 <0.0001 0.0001 0.0009 0.0049 0.0244 0.0479
Values are given as mean (min–max). TOF ratio values differed significantly between the recovered and partly recovered groups at all time points (𝑃 < 0.05).
TOF ratio: train-of-four ratio.
TOFR ≥ 90% is used as a clinical indicator of recovery from
NMB after NMB reversal [7]. TOFR exceeded 90% in all
patients in the recovered group at 3min after the first dose of
sugammadex administration. In the partly recovered group,
no patients showed TOFR above 90% at 3min after the first
dose of sugammadex administration.We therefore concluded
that an additional dose of sugammadex can be considered
unnecessary if TOFR is ≥90% at 3min after sugammadex
administration.
We used TOFR as the optimum indicator of recovery
from NMB after sugammadex administration for the fol-
lowing two reasons. When evaluating recovery from NMB
after sugammadex administrationwith reference toT1 height,
comparisons must be made with control values taken before
administration of the neuromuscular blocking agent. This
control value is taken before surgery and is thus susceptible
to the influence of slight positional changes and so forth
during surgery. We therefore considered that T1 height
would bemuchmore susceptible tomeasurement errors than
TOFR. Also, TOFR is known to recover more quickly than
T1 height with sugammadex-induced NMB reversal [8, 9],
unlike in neostigmine-inducedNMB reversal or spontaneous
recovery. We therefore considered TOFR as a more suitable
indicator for quickly determining the need for additional
administration of sugammadex after the first dose.
Recurarization after insufficient doses of sugammadex
has been reported in adults at around 20min after sug-
ammadex administration [3]. When postoperative NMB
reversal is insufficient, the risk of postoperative respiratory
complications such as aspiration is increased, potentially
compromising airway maintenance [10]. The ability to deter-
mine the necessity for additional sugammadex doses at 3min
after first dose would largely remove the dangers of recu-
rarization and contribute to cutting the risks of postoperative
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respiratory complications. The ability to determine at an
early stage the suitability of additional sugammadex doses
and NMB recovery could also lead to shorter times in the
operating theatre and reductions in overall costs.
Sugammadex is a highly safe drug with few serious side
effects. In phase I clinical trials, human subjects receiving
a high intravenous dose of 96mg/kg only showed taste
disturbance as a characteristic adverse reaction [11]. Overdose
in itself is thus not particularly problematic, and the risks of
underdose would not seem to warrant a deliberate reduction
in dose. However, if the sugammadex dose can be appro-
priately reduced, it may contribute to reductions in drug
costs. For example, the recommended dose of sugammadex
for reversal of moderate NMB in a patient weighing 120 kg
is 240mg (2mg/kg). In this case, it would be necessary to
use either two vials of 200mg preparation or one vial of
500mg preparation. If, however, it could be determined in
a short period of time that a dose of 200mg (1.67mg/kg)
was sufficient for the patient, only one 200mg vial would be
needed, thus reducing the drug cost.
Suitable reductions in sugammadex dose would also
likely prove advantageous in the following situations.
Where reoperation requiring tracheal intubation and
NMB is performed shortly after sugammadex administra-
tion, the benzylisoquinoline-based agents mivacurium and
cisatracurium are suitable alternatives in some countries, as
they do not bind to sugammadex. However, these agents
are unapproved and therefore unavailable in other countries,
including Japan. If suxamethonium is used, tracheal intuba-
tion can be performed rapidly, but subsequent maintenance
of NMB is difficult. In these situations, the only alternative is
to readminister rocuronium while remaining mindful of the
fact that NMB reversal has been induced by sugammadex.
At these times, keeping the sugammadex dose as low as
possible becomes advantageous. According to Cammu et al.
[12], when administering 0.6mg/kg rocuronium, followed by
the recommended dose of 4mg/kg sugammadex during deep
NMB of PTC 1-2, and then readministering rocuronium at
1.2mg/kg at 5min after sugammadex, the time for rocuro-
nium to exert its action was 3.06min (range, 1.92–4.72min),
notably slower than the original time for rocuronium to
take effect when administered at 1.2mg/kg. As sugammadex
and rocuronium molecules normally bind in a 1 : 1 ratio, a
lower amount of sugammadex in the body would be more
conducive to reoccurrence of NMB when rocuronium is
readministered.
The present study targeted patients ≥20 years old, and
we do not know if similar results would be seen in children.
Results might also differ in patients susceptible to peripheral
nerve damage, such as diabetic patients. Sugammadex dose
reduction in these patients is a topic for further research.
5. Conclusion
In adult patients with ASA physical status I-II, an additional
dose of sugammadex appears unnecessary if TOFR is≥90% at
3min after initial administration. This suggests that safe and
suitable reductions in sugammadex dose may be possible.
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